2-氟-3-(4-羟基苯基)丙酸乙酯 | 74649-83-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 2-氟-3-(4-羟基苯基)丙酸乙酯
• 英文名称: ethyl 2-fluoro-3-(4-hydroxyphenyl)propionate
• 英文别名: ethyl 2-fluoro-3-(4-hydroxyphenyl)propanoate
• CAS: 74649-83-5
• 化学式: C₁₁H₁₃FO₃
• 分子量: 212.221
• InChiKey: FUWMNEYZANJWOB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2',6'-二甲基-3-联苯基)甲醇 、 2-氟-3-(4-羟基苯基)丙酸乙酯 在 lithium hydroxide monohydrate 、 三丁基膦 、 水 、 1,1'-azodicarbonyl-dipiperidine 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 3.0h， 生成 3-{4-[(2',6'-dimethylbiphenyl-3-yl)methoxy]phenyl}-2-fluoropropanoic acid
  参考文献：
  名称：

  Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists

  摘要：

  G protein-coupled receptor 40 (GPR40) is being recently considered to be a new potential drug target for the treatment of type 2 diabetes because of its role in the enhancement of free fatty acid-regulated glucose-stimulated insulin secretion in pancreatic beta-cells. We initially identified benzyloxyphenylproparoic acid (1b) (EC50 = 510 nM), which was designed based on the structure of free fatty acids, as a promising lead compound with GPR40 agonist activity. Chemical modification of compound 1b led to the discovery of 3-{4-[(2',6'-dimethylbiphenyl-3-yl)methoxy]-2-fluorophenyl}propanoic acid (4p) as a potent GPR40 agonist (EC50 = 5,7 nM). Compound 4p exhibited acceptable pharmacokinetic profiles and significant glucose-lowering effects during an oral glucose tolerance test in diabetic rat;. Moreover, no hypoglycemic event was observed even after administration of a high dose of compound 4p to normal fasted rats. These pharmacological results suggest that GPR40 agonists might be novel glucose-dependent insulin secretagogues with little or no risk of hypoglycemia.

  DOI：

  10.1021/jm101405t
• 作为产物：
  描述：

  ethyl (E)-3-[4-[(4-chlorophenyl)methoxy]phenyl]-2-fluoroprop-2-enoate 生成 2-氟-3-(4-羟基苯基)丙酸乙酯
  参考文献：
  名称：

  KAWAMATSU Y.; ASAKAWA H.; SARAIE T.; IMAMIYA E.; NISHIKAWA K.; HAMURO Y., ARZNEIMITTEL-FORSCH., 1980, 30, NO 4, 585-589

  摘要：

  DOI：

文献信息

• Phenylpropanoic acid derivatives
  申请人：Yasuma Tsuneo

  公开号：US20070155808A1

  公开（公告）日：2007-07-05

  The present invention provides a novel compound having a GPR40 receptor function modulating action, which is useful as an insulin secretagogue, a drug for the prophylaxis or treatment of diabetes and the like. A compound represented by the formula (I) wherein each symbol is as defined in the specification, a salt thereof and a prodrug thereof have unexpectedly superior GPR40 receptor agonist activity and also show superior properties as a pharmaceutical product, such as stability and the like. Thus, they can be safe and useful drugs for the prophylaxis or treatment of GPR40 receptor related conditions or diseases in mammals.

  本发明提供了一种新型化合物，具有GPR40受体功能调节作用，可用作胰岛素分泌剂，用于预防或治疗糖尿病等药物。化合物由式（I）表示，其中每个符号如规范中所定义，其盐和前药具有意外的优越的GPR40受体激动剂活性，并显示出卓越的药物产品特性，如稳定性等。因此，它们可以作为安全有效的药物，用于哺乳动物中预防或治疗与GPR40受体相关的疾病或病症。
• PHENYLPROPANOIC ACID DERIVATIVES
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1698624B1

  公开（公告）日：2012-06-27
• Kawamatsu; Asakawa; Saraie, Arzneimittel-Forschung/Drug Research, 1980, vol. 30, # 4, p. 585 - 589
  作者：Kawamatsu、Asakawa、Saraie、Imamiya、Nishikawa、Hamuro

  DOI：——

  日期：——
• US7585880B2
  申请人：——

  公开号：US7585880B2

  公开（公告）日：2009-09-08
• Design, Synthesis, and Biological Activity of Potent and Orally Available G Protein-Coupled Receptor 40 Agonists
  作者：Shinobu Sasaki、Shuji Kitamura、Nobuyuki Negoro、Masami Suzuki、Yoshiyuki Tsujihata、Nobuhiro Suzuki、Takashi Santou、Naoyuki Kanzaki、Masataka Harada、Yasuhiro Tanaka、Makoto Kobayashi、Norio Tada、Miyuki Funami、Toshimasa Tanaka、Yoshio Yamamoto、Kohji Fukatsu、Tsuneo Yasuma、Yu Momose

  DOI：10.1021/jm101405t

  日期：2011.3.10

  G protein-coupled receptor 40 (GPR40) is being recently considered to be a new potential drug target for the treatment of type 2 diabetes because of its role in the enhancement of free fatty acid-regulated glucose-stimulated insulin secretion in pancreatic beta-cells. We initially identified benzyloxyphenylproparoic acid (1b) (EC50 = 510 nM), which was designed based on the structure of free fatty acids, as a promising lead compound with GPR40 agonist activity. Chemical modification of compound 1b led to the discovery of 3-4-[(2',6'-dimethylbiphenyl-3-yl)methoxy]-2-fluorophenyl}propanoic acid (4p) as a potent GPR40 agonist (EC50 = 5,7 nM). Compound 4p exhibited acceptable pharmacokinetic profiles and significant glucose-lowering effects during an oral glucose tolerance test in diabetic rat;. Moreover, no hypoglycemic event was observed even after administration of a high dose of compound 4p to normal fasted rats. These pharmacological results suggest that GPR40 agonists might be novel glucose-dependent insulin secretagogues with little or no risk of hypoglycemia.